Controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile3 entries
2023
Oral phenylephrine effectiveness controversy
An FDA advisory committee concluded that available scientific data did not support oral phenylephrine’s effectiveness at the recommended dose as a nasal decongestant. Because some NyQuil formulations have contained oral phenylephrine, the conclusion became relevant to the brand and to the wider OTC cold-medicine category. The FDA stated that the advisory recommendation was not itself a final agency decision.
2022
NyQuil cooking social-media controversy
A social-media-associated practice involving cooking or heating chicken with NyQuil led the FDA to warn consumers not to heat or cook food with the medicine. The FDA cited risks from concentrating the ingredients and inhaling vapors. The practice was not an intended use of the product.
2007
Advertising claims challenge before the National Advertising Division
The National Advertising Division reviewed a challenge involving P&G advertising for NyQuil Multi-Symptom Cold/Flu Relief and recommended modifications to certain claims. The matter concerned advertising substantiation and presentation.